The absence of approved treatments for a rare disease escalates pipeline assets into high-stakes acquisition and registration races.
With no approved therapies on the market, drugmakers are aggressively acquiring or fast-tracking clinical candidates to secure the definitive first-mover advantage in Stargardt disease.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
In a fatal disease that never had an approved therapy anywhere, securing the first-ever worldwide registration is the definitive first-mover prize the absence of competitors escalates.
An $800 million pipeline acquisition highlights how the lack of any approved therapies is triggering a high-stakes clinical race to capture the Stargardt disease market.
The absence of any approved therapy for Stargardt disease drives the developer to secure multiple expedited regulatory pathways to lock in a historic first-mover advantage.